CAR-T strategies targeting ROR1+ cancer cells have also been developed and shown to have limited toxicity in primates and should be efficacious in eradicating ROR1+ CLL [24], but CAR-T efficacy in solid cancers generally has yet to be established. Here, ROR1 is linked to cancer.